Novel Vaccine Platform

  • Tunable, rationally-designed, self-adjuvanting vaccine platform based on a highly specific and effective, novel TLR2 adjuvant

  • Elicits a tailored immune response specific for the disease and antigen

  • Universal application to all antigens

  • Potential to synergize with and overcome resistance to checkpoint inhibitors and other immunotherapies